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during CRRT. Dabigatran plasma clearance varied between 91 and 169 mL/min
during IHD and remained constant during treatments. A 33% rebound in
dabigatran levels occurred in one patient after IHD but incomplete data were
available in others; rebound was not observed post-CRRT. Prolonged IHD
(8–18 h, continuously) appeared sufficient to render dabigatran subtherapeutic,
including the case requiring urgent surgery; four hours was insufficient in one
case. Of the four patients with bleeding, one expired shortly after IHD.
Conclusions: IHD enhanced dabigatran elimination more than CRRT and com-
plications were not observed. Dialysis decisions, including modality and duration
must be individualised based on a risk-benefit assessment.
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RETINAL ABNORMALITIES IN THE C3
NEPHROPATHIES AND THE RISK OF
VISUAL IMPAIRMENT
D COLVILLE1, L AMOS1, P HUGHES3, K NICHOLLS3, H MACK2,
RCA SYMONS1,2, JD SMITH1, J SAVIGE1
1The University of Melbourne Department of Medicine, Melbourne Health and
Northern Health, Melbourne; 2Eye Surgery Associates, East Melbourne;
3Department of Nephrology, Royal Melbourne Hospital, Melbourne, Australia
Aims: To determine retinal abnormalities in 8 affected individuals from 7 families
with DDD and two unrelated individuals with atypical HUS.
Background: The C3 nephropathies comprise dense deposit disease (DDD, for-
merly known as membranoproliferative glomerulonephritis type II), C3 glomeru-
lonephritis and atypical haemolytic uraemic syndrome. All these diseases may be
associated with mutations in the Complement Factor H gene (CFH), as well as
other genes. Retinal drusen have been described in DDD, and we describe here
retinal abnormalities in DDD and atypical HUS.
Methods: All individuals with DDD were examined by an ophthalmologist, and
together with the patients with atypical HUS underwent retinal imaging and
optical coherence tomography (OCT).
Results: Ocular symptoms in patients with DDD included impaired night vision,
which was common and occurred early, and impaired peripheral vision. Individ-
uals with DDD had multiple small basal laminar drusen (<125 um), large soft
drusen, or both. Drusen were first seen in adolescence, with pigmentation and
haemorrhage occurring later. Optical coherence tomography (OCT) demon-
strated the drusen location beneath the retinal pigment epithelium, secondary
atrophy of the neuroretina in about half the individuals, and, in one, the further
complications of sub-retinal choroidal neovascular membranes, pigment epithe-
lial detachment and atypical serous retinopathy.
One of the two individuals with atypical HUS had large soft macular drusen
(> 125 um) identical to those seen in DDD.
Conclusions: Individuals with C3 nephropathy should be assessed
ophthalmologically for macular disease at diagnosis, and monitored annually
thereafter. They should be advised to present immediately if their vision deterio-
rates. Laser therapy prevents some retinal complications, and biological treat-
ments offer further hope.
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AUSTRALIAN PATIENTS
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Aim: To report on Australian patients with aHUS who have received the com-
plement inhibitor, eculizumab, on compassionate grounds.
Background: aHUS is an ultra-rare, genetic, life-threatening disease associated
with high rates of end-stage kidney disease and premature death. Chronic, uncon-
trolled complement activation causes systemic thrombotic microangiopathy
(TMA), acute kidney injury and multi-organ system damage. Prior to the advent
of eculizumab, 33–40% of patients with aHUS died or reached ESKD with their
first manifestation of the disease.
Methods: Patients with a clinical diagnosis of aHUS who have received com-
passionate eculizumab therapy have been included in this case series.
Results: 10 patients with aHUS began treatment with eculizumab between 2010
and 2013. 80% of patients were female with presentation at 7 months to 40 years
of age. The median duration of treatment was 12 months (range 4–42 months).
All patients had haematological evidence of TMA and organ damage, had
ADAMTS-13 activity of >5% and were negative for STEC. Five patients dem-
onstrated multiple progressive extra-renal complications including severe hyper-
tension, cardiomyopathy and neurological complications including headaches,
fatigue, drowsiness, blurred vision, poor balance and seizures.
Eculizumab was well tolerated and all patients remain on drug with median
follow-up of 18 months. All 9 surviving patients had a rapid haematological
response with resolution of TMA and discontinued plasma exchange/infusions
(PE/PI). Five patients (50%) were dialysis-dependent at initiation of eculizumab.
Treatment with eculizumab was able to eliminate dialysis in 4 of these 5 (80%)
patients. All patients experienced improvement or stabilisation of extra-renal
manifestations.
Conclusions: aHUS is a severe multi-system disease and eculizumab treatment is
a promising therapy that allows for preservation of renal function and elimination
of dialysis and PE/PI.
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FOCAL SEGMENTAL GLOMERULOSCLEROSIS –
PRESENTING FEATURES, TREATMENT
AND OUTCOMES IN FAR NORTH
QUEENSLAND ADULTS
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Aim: To describe the clinical features, treatment and outcomes in adult patients
with Focal Segmental Glomerulosclerosis (FSGS) presenting in Far North
Queensland.
Background: FSGS is a common cause of end stage kidney disease (ESKD)
understudied within the Australian population. The incidence of ESKD attrib-
uted to FSGS is increasing worldwide.
Methods: A retrospective review on 47 patients with biopsy confirmed FSGS
between January 1997 and December 2013 at Cairns Hospital renal unit. Patients
were located through the local biopsy database of 790 biopsies. Presenting fea-
tures, secondary causes, prognostic factors, treatment modality and outcomes
(doubling of serum creatinine, ESKD, death) were examined.
Results: Patients were followed on average for 4.8 years (range 2 months to 16
years). The mean age was 45 years with 50% of Aboriginal and Torres Strait
Islander origin. Secondary causes included obesity (45%), hepatitis (6.8%) and
additional glomerulonephritis (27%). FSGS not otherwise specified (NOS) was
the most common variant (83%). Renin angiotensin system inhibitors and immu-
nosuppression were commonly given (70% and 29% respectively). Of those given
steroids, 45% responded and the remainder had an equal distribution of depend-
ence or resistance. Eight patients died (17%), 14 doubled their serum creatinine
(30%) and 13 progressed to ESKD (30%) within an average of 4.3 years. The
number of patients was too few to make any statistically significant conclusions
regarding prognostic factors.
Conclusions: FSGS holds serious implications for patients with 40% progressing
to the combined outcome. The Aboriginal and Torres Strait Islander community
is over-represented in this population. Rates of immunosuppression treatment
suggest either a significant proportion of secondary FSGS or under-treatment of
primary FSGS in the region. Detailed description of prognostic factors remains to
be clarified.
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CORRELATION BETWEEN IMMUNOGLOBULIN G4
(IgG4) GLOMERULAR STAINING AND
ANTI-PHOSPHOLIPASE A2 RECEPTOR ANTIBODY
(PLA2R) TESTING IN MEMBRANOUS
NEPHROPATHY
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Aim: To investigate the correlation of PLA2R antibody with clinical, biochemi-
cal and histological markers of membranous nephropathy.
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